Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Immunotherapy and targeted agents for elderly lung cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.11.19
Views: 334
Rating:

Dr Lore Decoster - University Hospital Brussels, Brussels, Belgium

Dr Lore Decoster speaks to ecancer at the SIOG 2019 meeting in Geneva about the use of immunotherapy and targeted agents to treat elderly lung cancer patients

She explains that clinicians aren't certain of how the immune system reacts to immunotherapy in older patients and, although some retrospective studies have indicated no differences, one study suggested that patients aged over 80 benefit less.

Dr Decoster adds that while some targeted agents are useful because the targets are more frequent in older patients, the toxicities need to be observed carefully.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation